While both c‐Myc‐i8 (IC50 of 94.0 μM) and c‐Myc‐i10 (11.7 μM) exhibited considerable efficacy, the latter showed an eight‐fold improvement in its performance against prostate cancer compared to 10058‐F4. The gene discussed is MYC; the disease is prostate carcinoma.